Infectious Diseases: Prevention and Control

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Tropical Diseases 2018: Dengue epidemiology and vaccine: Current status

Dengue viruses are members of the genus Flavivirus within the family Flaviviridae. There are 4 dengue virus serotypes (type 1, 2, 3, and 4), all of which circulate globally. Most of dengue virus infections are asymptomatic. For clinical management of WHO classify dengue illness as (1) Dengue with or without warning signs for progression towards severe dengue and (2) severe dengue. There is no specific antiviral treatment for dengue illness. Clinical management is based on supportive therapy, preliminary judicious monitoring of intravascular volume replacement. Until the recent vaccine licensure, the only approach to control and prevent transmission of dengue virus through interventions targeting for vectors. Dengue virus infection induces high titer of neutralizing antibodies, which is believed to an important component of a protective immune response. Following infection with one dengue virus serotype, protection against the infective serotype (homotypic protection) considered long-lasting. Temporary cross-protection is induced to other serotypes (heterotypic protection), lasting 2 years on average. One dengue has been licensed in several countries (CYD-TDV or Dengvaxia); this is a live attenuated (recombinant) tetravalent vaccine. Other than this, 2 more vaccines are under evaluation. World Health Organization (WHO) states countries should introduce vaccines only in geographical settings with a high burden of disease (seroprevalence should be approximately 70% and greater in defined age group). Dengue vaccine introduction should be a part of a comprehensive dengue control strategy, including well-executed and vector control, evidence-based best practices for clinical care for all patients with dengue illness and strong dengue surveillance. However, using surveillance data to monitor the population impact of a vaccination program may be challenging as to year-to-year variability in dengue virus transmission may be greater than the expected vaccine impact on dengue illness.


Dengue Vaccine is an antibody used to forestall dengue fever in people. Starting in 2019, one form is industrially accessible, known as CYD-TDV, and sold under the brand name Dengvaxia. The immunization is just suggested in the individuals who have recently had dengue fever or populaces in which a great many people have been recently contaminated. The estimation of the antibody is restricted by the way that it might expand the danger of extreme dengue in the individuals who have not recently been tainted. It is given as three infusions longer than a year.


Regular reactions incorporate cerebral pain, torment at the site of infusion, and general muscle torments. Extreme symptoms may incorporate hypersensitivity. Use isn't suggested in individuals with poor invulnerable capacity. The security of utilization during pregnancy is hazy. Dengvaxia is a debilitated yet live antibody and works by setting off an insusceptible reaction against four kinds of dengue infection.


Starting in 2016, the dengue immunization had been affirmed for clinical use in eleven nations and in 2019, was endorsed for clinical use in the United States. It is on the World Health Organization's List of Essential Medicines, the most secure and best drugs required in a wellbeing framework. In Indonesia, it costs about US$207 for the suggested three portions starting in 2016. Advancement of dengue antibodies started during the 1920s, however, was blocked by the need to make resistance against every one of the four dengue serotypes. A few other antibody applicants being developed including live weakened, inactivated, DNA, and subunit immunizations.


Proof demonstrates that CYD-TDV is in part viable in forestalling contamination, yet it may prompt a higher danger of serious ailment in the individuals who have not been recently tainted and afterward proceed to get the illness. It isn't clear why the inoculated seronegative populace have progressively genuine antagonistic results. Conceivable speculation is the wonder of immune response subordinate upgrade.


In 2017, the producer suggested that the immunization just be utilized in individuals who have recently had a dengue disease as in any case there was proof it might compound ensuing contaminations. The underlying convention didn't require pattern blood tests preceding immunization so as to set up a comprehension of the expanded danger of serious dengue in members who had not been recently uncovered. In November 2017, Sanofi recognized that a few members were put in danger of extreme dengue in the event that they had no earlier introduction to the contamination; hence the Philippine government suspended the mass inoculation program with the support of the WHO which started a survey of the wellbeing information.


Stage III preliminaries in Latin America and Asia required more than 31,000 youngsters between the ages of two and 14 years. In the primary reports from the preliminaries, antibody adequacy was 56.5% in the Asian examination and 64.7% in the Latin American investigation in patients who got in any event one infusion of the immunization. Viability differed by serotype. In the two preliminaries antibody diminished by about 80% the number of extreme dengue cases. An investigation of both the Latin American and Asian examinations at the third year of follow-up demonstrated that the viability of the immunization was 65.6% in forestalling hospitalization in youngsters more established than nine years old, yet impressively more noteworthy (81.9%) for kids who were seropositive (showing past dengue contamination) at the gauge. The immunization arrangement comprises three infusions at 0, 6, and a year. Tradenamed Dengvaxia, it is endorsed for use for those matured nine and more seasoned and can forestall every one of the four serotypes.


A test dengue vaccine has indicated promising early outcomes in an enormous, multicountry preliminary, however, basic inquiries stay about its adequacy and security. Still hazy, for instance, is whether the immunization—which had adequacy of 80.2% in the examination—may expand illness seriousness in certain beneficiaries, as occurred with a dengue antibody given to 1 million youngsters in the Philippines before the issue turned out to be clear in 2017.


Dengue infection, which is transmitted to people by mosquitoes, contaminates around 390 million individuals every year, and the malady is quickly expanding its stretch the world over. In spite of the fact that it ordinarily causes flulike indications or none by any stretch of the imagination, serious cases can prompt hemorrhagic fever, stun, and even demise. So even not exactly perfect antibodies "can, in any case, have a general wellbeing sway," says Derek Wallace, a clinician who heads the R&D venture at pharmaceutical organization Takeda in Cambridge, Massachusetts.


To test their new antibody, which depends on a debilitating strain of the dengue infection, Wallace and partners arbitrarily conveyed it or a fake treatment to 20,000 kids, matured 4 to 16, in eight nations across Asia and Latin America, where the ailment is endemic. A year after members got their second and last portion, the analysts looked at what number of individuals in the fake treatment and immunization bunches created affirmed instances of contamination with any of the four unique strains, or serotypes, of dengue infection. The immunization had 97.7% adequacy against the dengue 2 serotype, the group reports today in The New England Journal of Medicine (NEJM). That figure dropped to 73.7% for serotype 1 and 62.3% for serotype 3; there were too barely any contaminations with serotype 4 to arrive at any resolutions.


In members who had affirmed dengue contaminations, the antibody diminished the danger of hospitalization by 95.4%. "The outcomes are exceptionally promising," says Jeremy Farrar, leader of the Wellcome Trust biomedical cause in London, who is a dengue analyst.


The new antibody's solid security against serotype 2 is nothing unexpected, says In-Kyu Yoon, a dengue immunization pro in Bethesda, Maryland, who is a senior guide to the International Vaccine Institute and who served on a nonpartisan warning board for Takeda. That is on the grounds that the "spine" of the immunization is an innocuous form of dengue infection serotype 2. A couple of qualities from the other three serotypes have been placed into the infection to make the "tetravalent" immunization.

Special Features

Full Text


Track Your Manuscript

Media Partners